Manufacturing advanced therapies like CAR-T cell therapy and gene therapies involves a highly complicated process including extracting cells, flying them to another country for gene editing, and then flying them back for infusion. This process needs to be completed quickly due to the viability of the product and the critical condition of the patients. The scalability of these technologies is hindered by several kinks in the complex manufacturing processes. Companies like Bristol Myers Squib have invested heavily in acquiring expertise in delivering these advanced therapies, which require a high level of process expertise and scale. The traditional pharma model of mass-producing pills is inadequate for these personalized and complex therapies, and the future of pharmaceuticals will likely involve more of such intricate and large-scale products.

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode